Login / Signup

In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics.

Axel SteinbrueckAdam C SedgwickHai-Hao HanMichael Y ZhaoSajal SenDan-Ying HuangYi ZangJia LiXiao-Peng HeJonathan L Sessler
Published in: Chemical communications (Cambridge, England) (2021)
We report here strategic functionalization of the FDA approved chelator deferasirox (1) in an effort to produce organelle-targeting iron chelators with enhanced activity against A549 lung cancer cells. Derivative 8 was found to have improved antiproliferative activity relative to 1. Fluorescent cell imaging revealed that compound 8 preferentially localises within the lysosome.
Keyphrases
  • single cell
  • cancer therapy
  • living cells
  • high resolution
  • small molecule
  • quantum dots
  • risk assessment
  • bone marrow
  • mass spectrometry
  • water soluble